JPMorgan Chase & Co. initiated coverage on shares of Septerna (NASDAQ:SEPN - Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The firm issued an overweight rating and a $38.00 price target on the stock.
Several other brokerages also recently commented on SEPN. Cantor Fitzgerald began coverage on shares of Septerna in a research note on Tuesday. They issued an "overweight" rating and a $50.00 target price for the company. Wells Fargo & Company assumed coverage on shares of Septerna in a research note on Tuesday. They issued an "overweight" rating and a $43.00 price target for the company. Finally, TD Cowen assumed coverage on shares of Septerna in a research note on Tuesday. They issued a "buy" rating for the company.
Read Our Latest Stock Analysis on SEPN
Septerna Trading Up 2.4 %
Shares of SEPN stock traded up $0.57 during trading hours on Tuesday, reaching $24.12. 185,032 shares of the company were exchanged, compared to its average volume of 199,049. Septerna has a fifty-two week low of $18.62 and a fifty-two week high of $26.34.
Insider Transactions at Septerna
In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the business's stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Further Reading
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
